Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country